Last reviewed · How we verify
R-mabHDI and ABVD
R-mabHDI is a monoclonal antibody targeting histone deacetylase inhibition combined with ABVD chemotherapy to enhance anti-tumor immune response and cytotoxicity in lymphomas.
R-mabHDI is a monoclonal antibody targeting histone deacetylase inhibition combined with ABVD chemotherapy to enhance anti-tumor immune response and cytotoxicity in lymphomas. Used for Hodgkin lymphoma (in combination with ABVD).
At a glance
| Generic name | R-mabHDI and ABVD |
|---|---|
| Also known as | R-mabHDI |
| Sponsor | American Scitech International |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
R-mabHDI appears to be an investigational monoclonal antibody designed to work synergistically with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), a standard chemotherapy regimen for Hodgkin lymphoma. The combination likely leverages immunomodulation and epigenetic targeting to improve treatment efficacy. ABVD provides direct cytotoxic effects while the mAb component may enhance immune recognition and tumor cell death.
Approved indications
- Hodgkin lymphoma (in combination with ABVD)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Cardiotoxicity
- Alopecia
- Peripheral neuropathy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |